Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma

Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma

Abstract Background Atezolizumab plus bevacizumab is recommended as a first-line treatment for unresectable hepatocellular carcinoma (uHCC). A subgroup analysis of the IMbrave150 trial showed shorter overall survival (OS) in uHCC patients with stable disease (SD) than patients with complete response...

Full description

Saved in:
Bibliographic Details
Main Authors: Yoshihisa Kodama, Kazuomi Ueshima, Michihisa Moriguchi, Yoshitaka Inaba, Tatsuya Yamashita, Hideki Iwamoto, Makoto Ueno, Sadahisa Ogasawara, Teiji Kuzuya, Takahiro Kodama, Yozo Sato, Toshifumi Tada, Kaoru Tsuchiya, Hideyuki Nishiofuku, Koichiro Yamakado, Miyuki Sone, Masafumi Ikeda, Tetsuo Takehara, Tetsutaro Hamano, Masatoshi Kudo
Format: Article
Language:English
Published: BMC 2025-03-01
Series:BMC Cancer
Subjects:
Atezolizumab
Bevacizumab
Conversion
Hepatocellular carcinoma
Multidisciplinary treatment
Protocol
Online Access:https://doi.org/10.1186/s12885-025-13648-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-13648-5

Similar Items